InMed Pharmaceuticals (INM) Q4 2024 Earnings
INM·Reported February 12, 2025·Before market open
InMed Pharmaceuticals reported Q4 2024 revenue of $772.5M. Diluted EPS came in at $-3.64.
Revenue
$772.5M
Diluted EPS
$-3.64
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about InMed Pharmaceuticals's Q4 2024 earnings report.
InMed Pharmaceuticals (INM) reported Q4 2024 earnings on February 12, 2025 before market open.
InMed Pharmaceuticals reported revenue of $772.5M and diluted EPS of $-3.64 for Q4 2024.
You can read the 10-Q periodic report (0001213900-25-013063) directly on SEC EDGAR. The filing index links above go to sec.gov.